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Abstract. We estimated the incidence of watery diarrhea in the community before and after introduction of the
pentavalent rotavirus vaccine in León, Nicaragua. A random sample of households was selected before and after
rotavirus vaccine introduction. All children < 5 years of age in selected households were eligible for inclusion. Children
were followed every 2 weeks for watery diarrhea episodes. The incidence rate was estimated as numbers of episodes per
100 child-years of exposure time. A mixed effects Poisson regression model was fit to compare incidence rates in the pre-
vaccine and vaccine periods. The pre-vaccine cohort (N = 726) experienced 36 episodes per 100 child-years, and the
vaccine cohort (N = 826) experienced 25 episodes per 100 child-years. The adjusted incidence rate ratio was 0.60 (95%
confidence interval [CI] 0.40, 0.91) during the vaccine period versus the pre-vaccine period, indicating a lower incidence
of watery diarrhea in the community during the vaccine period.
INTRODUCTION
Diarrheal diseases cause 1.3 million deaths of children each
year and are an important cause of malnutrition, growth
retardation, and developmental delays.1–3 Although child
deaths caused by diarrhea have declined substantially since
the introduction of oral rehydration therapy, there has been
little change in diarrhea incidence in low and middle income
countries (LMICs) since the 1950s.4
Vaccines against rotavirus, one of the most common causes
of diarrhea,5 offer promise in reducing diarrhea incidence in
LMIC settings. Rotavirus vaccines show excellent protection
against rotavirus diarrhea in clinical trials conducted primar-
ily in the industrialized world.6,7 Evaluations of the vaccines’
effectiveness in LMICs report less robust protection.8–11
These evaluations have focused on the prevention of hospital-
izations and severe diarrhea, although little is known about
the vaccine’s effect on diarrhea incidence in the community.
However, the majority of rotavirus diarrhea cases are treated
at home: 80–85% of cases do not receive treatment at any
health facility.12
The goal of this study was to examine the childhood diar-
rhea incidence rate at the community level in Nicaragua, the
first LMIC to introduce the pentavalent rotavirus vaccine
(RV5, RotateqÒ) in 2006. We examined watery diarrhea inci-
dence in León, Nicaragua before and after RV5 introduction
using active surveillance. Because rotavirus traditionally has
a seasonal transmission pattern, we also examined changes in
seasonal patterns of diarrhea incidence.
METHODS
Setting. The study was performed in the municipality of
León, Nicaragua’s second largest city, with an estimated 2010
population of 192,164. Municipal water treatment plants have
been in continuous use in León since the 1990s. Improve-
ments in child mortality have been made in recent decades,13
however, diarrhea remains among the most important causes
of mortality and morbidity in children in León.14
Diarrhea incidence in Central America has two annual
peaks; the dry season peak is attributed primarily to rotavirus
infections, whereas the rainy season peak has traditionally
been attributed to bacterial pathogens, such as enterotoxi-
genic Escherichia coli and Shigella spp.15–17 Overall, rotavirus
was considered one of the most common causes of diarrhea
among Nicaraguan children before the immunization pro-
gram, isolated among 28% of children receiving care for diar-
rhea in health facilities.18
To reduce the burden of rotavirus diarrhea, Nicaragua
implemented a rotavirus immunization program with RV5 in
October 2006. Nicaraguan infants are offered the vaccine at the
age of 2, 4, and 6 months as part of the country’s Expanded
Program on Immunization (EPI).
Sample selection. Cohorts from two distinct periods were
examined in the study: before implementation of the immuni-
zation program, or, “pre-vaccine” (December 2000 to March
2001, and July 2002 to January 2003; broken into two segments
because of budgetary issues) and following implementation
of the immunization program, or, “vaccine” (January 2010 to
January 2011). The time periods were chosen to include an
equal number of months during the rainy and dry seasons.
In each time period, a random sample of households was
selected from the Health and Demographic Surveillance Site-
León (HDSS-León). The HDSS-León provides longitudinal
surveillance for a population-based sample of 28% of León’s
population, residing in 50 out of 208 randomly selected geo-
graphical clusters of equal population size19 (Figure 1). Chil-
dren < 5 years of age in each sampled household were eligible
for inclusion in the study. An “open cohort” design was used:
children were excluded from the study after their fifth birth-
day, and new infants born into the household or children
moving into the household during the study periods were
eligible for inclusion.
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Data collection and study instruments. Female field workers
visited sampled households every 2 weeks and performed
household interviews. The interview was conducted with the
mother or with the child’s caretaker if the mother was
unavailable. Quality control of the interviews and data collec-
tion was performed by the field supervisor with systematic
and random evaluations.
The study instrument contained information on diarrhea
episodes and clinical characteristics as reported by the mother
or caretaker, family characteristics, household characteristics,
breastfeeding history, and during the vaccine period only, a
detailed rotavirus vaccine history taken from the child’s
immunization card.
At each interview, the field worker asked about all diarrhea
episodes within the past 14 days, and collected information on
the presence of vomiting, fever, and the presence of visible
blood in the stool. A clinical definition of watery diarrhea
suggestive of rotavirus infection was developed based on the
literature, and defined as a diarrhea episode with a maximum
of four or more bowel movements per 24 hour period, with
the presence of vomiting or fever (or both), and without any
blood in the stool.20–25 An episode was considered to be new
if the participant experienced at least 3 days without an episode
before the onset of a new episode. In addition to diarrhea
episodes, breastfeeding status, and rotavirus vaccine status
were also updated at each household visit.
The study was approved by the Institutional Review Boards
of the Universidad Nacional Autónoma de Nicaragua, León
and the University of North Carolina at Chapel Hill. Informed
consent was obtained from a parent or legal guardian of
each participant.
Statistical analysis. Mixed effects linear and logistic regres-
sion models were used to compare participant characteristics
in the pre-vaccine and vaccine periods. The mixed effects
models allowed for possible correlation between multiple par-
ticipants living in the same household. The incidence rate of
watery diarrhea was estimated as the number of episodes per
100 child-years of exposure time, and was stratified by age
group (0–23 months, 24–59 months). The exposure time was
estimated at the time each child was followed during the study
and at-risk for a watery diarrhea episode; days with watery
diarrhea were not included in the exposure time. Official rain-
fall data from León’s regional airport26 were used to assign
each month of the study as either rainy (³ 6 mm per month)
or dry (< 6 mm per month).
A mixed effects Poisson regression model was fit to com-
pare incidence rates in the pre-vaccine and vaccine periods.
The mixed effects model allowed for possible correlation
between multiple participants living in the same household as
well as multiple measurements for each individual, and also
allowed for adjustment for potential confounders. Incidence
rates were compared between the rainy and dry seasons. Fur-
thermore, in the vaccine period, incidence rates were com-
pared between fully or partially immunized children and
unimmunized children. These results were stratified by age
group because of potential differences in the vaccine’s effect
by age group.
RESULTS
A total of 726 children were enrolled during the pre-vaccine
period and followed for 306.9 years of exposure time; 826 chil-
dren were enrolled in the vaccine period and followed for
610.6 years of exposure time. Characteristics of children during
the pre-vaccine and vaccine periods are shown in Table 1.
Households observed during the pre-vaccine period had fewer
indoor toilets compared with the vaccine period (46.7% versus
Figure 1. Map of León, Nicaragua: Geographic clusters and households included in HDSS-León surveillance site.
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80.1%, P < 0.001) and mothers of children in the vaccine period
were slightly more likely to be employed (33.3% versus 40.0%,
P < 0.001) and have completed a basic level of education
(82.4% versus 90.1%, P = 0.007). In all, 78.1% of vaccine
period children were eligible to receive the rotavirus vaccine
based on having a birthday on or after August, 2006. Upon
study entry, 67.3% of all children in the vaccine period had
received at least one dose of the rotavirus vaccine; among
children < 24 months of age, 86.6% had received at least one
dose of vaccine, whereas among children 24 to 60 months
of age, 53.2% of children had received at least one dose
of vaccine.
The crude watery diarrhea incidence rate was 35.8 episodes
per 100 child-years in the pre-vaccine period and 24.9 epi-
sodes per 100 child-years in the vaccine period (Table 2). Inci-
dence rates stratified by age group are shown in Figure 2;
among both age groups there was a lower watery diarrhea
incidence rate in the vaccine period.
Table 3 shows the adjusted incidence rate ratios (IRRa) of
watery diarrhea in the vaccine versus pre-vaccine periods, as
estimated by the mixed effects Poisson regression model. In
the model, we adjusted for sex, breastfeeding, maternal edu-
cation, maternal employment status, living in a household
with a dirt floor, indoor municipal water source, season, and
indoor toilet. Among all ages, the IRRa was 0.60 (95% confi-
dence interval [CI] 0.40, 0.91) in the vaccine period as com-
pared with the pre-vaccine period (“overall effect”). Among
children < 24 months of age the IRRa was 0.63 (95% CI 0.37,
1.05), whereas among children between 24 and 59 months
of age the IRRa was 0.56 (95% CI 0.32, 1.07). Among unim-
munized children only, the IRRa was 0.27 (95% CI: 0.13,
0.60) in the vaccine period as compared with the pre-vaccine
period; this result is consistent with an indirect effect of the
immunization program, but could also be caused by other
differences between the pre-vaccine and vaccine period. Dur-
ing the vaccine period, there were no significant differences
in watery diarrhea incidence rate observed between immu-
nized or partially unimmunized children as compared with
unimmunized children, stratified by age group (“direct effect”).
In both time periods, there was also no difference in diarrhea
incidence detected between the rainy seasons as compared
with the dry season.
DISCUSSION
Using active community surveillance in León, Nicaragua,
we observed a 40% lower incidence rate of watery diarrhea
episodes suggestive of rotavirus infection in the vaccine
period as compared with the pre-vaccine period. This reduc-
tion may be attributable to an overall protective effect of the
immunization program on immunized and unimmunized chil-
dren. The findings correlate with an observed decline in rota-
virus prevalence among children seeking care for diarrhea
in primary care clinics in León following the vaccine’s intro-
duction (14.0% in the pre-vaccine period versus 3.5% in the
vaccine period).27
The reduction in incidence observed among unimmunized
children provides evidence for herd protection conferred by
rotavirus immunization programs, as noted in prior studies.28
Surprisingly, the reduction in incidence among unimmunized
children (IRR = 0.27, 95% CI 0.13, 0.60) was greater than
Table 1









Age (mean in months [SD]) 25.3 [17.3] 28.9 [16.7] < 0.001
Sex, % male 51.2% (372/726) 50.4% (416/826) 0.73
Breastfeeding upon study enrollment 36.4% (247/679)† 34.0% (281/826) 0.34
Received at least one dose of rotavirus vaccine 0.0% (0/726) 67.3% (556/826) < 0.001
Household characteristics
Indoor municipal water source 94.1% (683/726) 97.0% (801/826) 0.05
Indoor toilet 46.7% (339/726) 80.1% (662/826) < 0.001
Concrete or tile floor (versus dirt floor) 72.9% (529/726) 77.2% (638/826) 0.008
Family characteristics
Mother completed fourth grade 82.4% (598/726) 90.1% (744/826) 0.007
Mother employed 33.3% (242/726) 40.0% (330/826) < 0.001
*P values based on mixed effects logistic or linear regression models with each characteristic as the outcome and an indicator for vaccine period as the sole covariate.
†6% of respondents chose not to answer this question.
Table 2
Watery diarrhea in pre-vaccine and vaccine periods
Pre-vaccine Vaccine
Number of households 411 530
Number of child participants 726 826
Numbers of children with
watery diarrhea episodes
91 117
Total number of watery
diarrhea episodes
110 152
Person-years in the study 306.9 610.6
Overall watery diarrhea incidence
(episodes per 100 child-years)
35.8 24.9
Figure 2. Watery diarrhea incidence by age group.
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among the population as a whole (IRR = 0.60, 95% CI 0.40,
0.91). An additional analysis found no differences in IRR
among unimmunized children living in neighborhoods with
low versus high vaccine coverage. Although our findings were
unexpected, a pattern of greater reductions in rotavirus diar-
rhea incidence among age groups with low versus high vaccine
coverage was previously observed in a United States study of
rotavirus diarrhea hospitalizations in the years before and after
vaccine introduction.29 In our study of a population with high
vaccine coverage, it is possible that our sample size of
unimmunized children was not large enough to detect a true
difference in incidence among unimmunized children as com-
pared with immunized children in the vaccine period. Alterna-
tively, it is conceivable that rotavirus immunization could
increase the risk of infection by a different diarrheal pathogen,
which would provide the unimmunized children an advantage
within this highly immunized population; however, there is no
biological explanation for this alternate hypothesis.
We did not observe a statistically significant direct effect of
the vaccine following introduction, which may be the result of
strong herd protection effects afforded by the immunization
program in a setting with high vaccine coverage. A similar
phenomenon was observed by Ali and others30 in an analysis
of herd immunity conferred by killed oral cholera vaccines.
To further investigate the direct effect of the rotavirus vac-
cine, we examined the dose effect by estimating age-stratified
incidence rates among those who had received one, two, or
three doses of vaccine. Among all age groups, the incidence
rate was lower among those who had received the full course
of vaccine than those who had received only two doses. How-
ever, among infants, the incidence rate among those receiving
the full course was no different than those receiving just one
dose. This could be explained by different exposures to
enteric pathogens among infants who had received one dose
as compared with those who had completed the full course; the
majority of infants who had received just one dose were two to
three months of age, were breastfed, and were less likely to
interact with their environment as compared with older infants,
who had received the full course.
This study highlights the importance of health and demo-
graphic surveillance systems in assessing disease rates in a pop-
ulation after an intervention. As the majority of diarrhea cases
are typically treated at home, they would not be captured by
more commonly used hospital-based surveillance systems.
Our study has several limitations. First, as an observational
study, we cannot prove that differences in incidence rates
between the pre-vaccine and vaccine periods were caused by
the immunization program and not by other factors. We did
observe certain improvements in living standards between the
two time periods. Although we included these socioeconomic
and household variables in our regression model, we did not
find them to be associated with watery diarrhea episodes. It is
possible, however, that factors associated with improvements
in living standards that we did not measure may have contrib-
uted to the overall decrease in diarrhea incidence rate
observed in the vaccine period. Second, this report does not
include laboratory data on the causes of diarrhea episodes,
but instead used a clinically defined watery diarrhea defini-
tion based on characteristics of rotavirus diarrhea reported in
the literature. Clearly, this definition is not as specific as lab-
oratory analysis, but allows a narrowing of diarrhea cases that
are more likely to be caused by rotavirus infection, and was
feasible in a community setting. As this study was conducted
in the community, the definition relied on the mother’s or
caretaker’s reports of fever during the episode. Prior studies
have shown that mothers detect fevers in their children with a
high sensitivity, although with a lower specificity than when a
thermometer is used by a health provider.31,32 Therefore, our
definition may have overestimated the incidence of episodes.
However, if the rate of overestimation was similar between
the pre-vaccine and vaccine periods, then our estimated IRR
would be biased towards the null, suggesting the true reduc-
tion in incidence associated with the introduction of the rota-
virus vaccine may be even greater than indicated by this
analysis. Finally, as rotavirus transmission can vary from year
to year, we cannot rule out that differences in watery diarrhea
incidence noted in the two time periods may be caused by
such year-to-year variability.
In summary, the changes in watery diarrhea incidence
observed in the two time periods support an overall and indi-
rect effect of the rotavirus immunization program at the com-
munity level. Future studies should attempt to identify the
etiologies of diarrhea that persist in the community following
vaccine introduction, to better design prevention programs
and further reduce the burden of childhood diarrhea.
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